Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6724769 | 0.78 | TSHR (0.35) | TSHR | |
| SCHEMBL530219 | 0.78 | TSHR (0.35) | TSHR | |
| SCHEMBL7787116 | 0.76 | TSHR (0.33) | TSHR | |
| SCHEMBL22325533 | 0.76 | TSHR (0.52) | TSHR | |
| SCHEMBL530220 | 0.76 | TSHR (0.33) | TSHR | |
| SCHEMBL11177532 | 0.75 | HCAR2 (0.32) | — | |
| SCHEMBL9296090 | 0.75 | — | — | |
| SCHEMBL6269584 | 0.74 | TSHR (0.32) | TSHR | |
| SCHEMBL530525 | 0.74 | LMNA (0.41) | TSHR | |
| SCHEMBL7879292 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115108927-A | Crystal forms and synthesis methods of (2R,6R) -hydroxynorketamine and (2S,6S) -hydroxynorketamine | 美国政府健康及人类服务部 | 2022-09-27 | — | — | CN | disclosed |
| CN-109311801-B | Crystal forms and synthesis methods of (2R,6R) -hydroxynorketamine and (2S,6S) -hydroxynorketamine | 美国政府健康及人类服务部 | 2022-07-26 | — | — | CN | disclosed |
| CN-109928901-B | Synthetic method of florfenicol intermediate | 上海医药工业研究院 | 2020-12-11 | — | — | CN | disclosed |
| EP-2588455-B1 | 2-QUINOLINYL-ACETIC ACID DERIVATIVES AS HIV ANTIVIRAL COMPOUNDS | GILEAD SCIENCES INC (US) | 2018-04-04 | — | — | EP | disclosed |
| US-9296758-B2 | 2-quinolinyl-acetic acid derivatives as HIV antiviral compounds | GILEAD SCIENCES, INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-20130210801-A1 | 2-QUINOLINYL-ACETIC ACID DERIVATIVES AS HIV ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-08-15 | — | — | US | disclosed |
| EP-2588455-A1 | 2 -QUINOLINYL- ACETIC ACID DERIVATIVES AS HIV ANTIVIRAL COMPOUNDS | Gilead Sciences, Inc. (US) | 2013-05-08 | — | — | EP | disclosed |
| WO-2012003498-A1 | 2 -QUINOLINYL- ACETIC ACID DERIVATIVES AS HIV ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2012-01-05 | — | — | WO | disclosed |
| US-7868023-B2 | Thiophene sulfoximines, compositions thereof, and methods of treating complement-mediated diseases and conditions | JANSSEN PHARMACEUTICA NV (BE) | 2011-01-11 | — | — | US | disclosed |
| US-7727976-B2 | Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs | XENOPORT, INC. (US) | 2010-06-01 | — | — | US | disclosed |
| EP-0777678-A4 | — | — | 1997-07-16 | — | — | EP | disclosed |
| EP-0777678-A1 | PNA COMBINATORIAL LIBRARIES AND IMPROVED METHODS OF SYNTHESIS | ISIS PHARMACEUTICALS, INC. (US) | 1997-06-11 | — | — | EP | disclosed |
| US-5622958-A | ANTITUMOR AGENTS, ANTICARCINOGENIC AGENTS | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 1997-04-22 | — | — | US | disclosed |
| US-5539083-A | FROM HALOACETYL HALIDE OR SULFONYLACETYL HALIDE, PROTECTED ALKYLENEDIAMINE, AND A DERIVATIVE OF A NUCLEIC ACID BASE | ISIS PHARMACEUTICALS, INC. (US) | 1996-07-23 | — | — | US | disclosed |
| WO-1996016655-A1 | NOVEL ENEDIYNE QUINONE IMINES AND METHODS OF PREPARATION AND USE THEREOF | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 1996-06-06 | — | — | WO | disclosed |
| WO-1995023163-A1 | PNA COMBINATORIAL LIBRARIES AND IMPROVED METHODS OF SYNTHESIS | ISIS PHARMACEUTICALS, INC. (US) | 1995-08-31 | — | — | WO | disclosed |
| EP-0508699-A1 | 9-Deoxo-8a-aza-8a-homoerythromycin a derivatives modified at the 4\"- and 8a-positions | MERCK & CO. INC. (US) | 1992-10-14 | — | — | EP | disclosed |
| EP-0191989-B1 | ANTIBIOTIC ISOXAZOLE DERIVATIVES, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1992-09-02 | — | — | EP | disclosed |
| US-4897489-A | 2-/5-OXO-2-TETRAHYDROFURANY4-3-OXOISOXOL-IDINE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1990-01-30 | — | — | US | disclosed |
| EP-0191989-A1 | Antibiotic isoxazole derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1986-08-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130210801-A1 | 2-QUINOLINYL-ACETIC ACID DERIVATIVES AS HIV ANTIVIRAL COMPOUNDS | NFATC1, ACIN1, ARF1 | TSHR 4474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.